Cymbalta Liver Safety Was Key Review Issue Delaying Lilly’s Antidepressant
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Initial approval of Lilly’s Cymbalta appears to have been delayed primarily by concerns over liver toxicity, FDA review documents for the serotonin-norepinephrine reuptake inhibitor show.